Compare LIF & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LIF | IMNM |
|---|---|---|
| Founded | 2008 | 2006 |
| Country | United States | United States |
| Employees | 547 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.8B |
| IPO Year | N/A | 2020 |
| Metric | LIF | IMNM |
|---|---|---|
| Price | $39.75 | $23.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | ★ $77.31 | $32.80 |
| AVG Volume (30 Days) | 1.2M | ★ 1.2M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.40 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $6,941,000.00 |
| Revenue This Year | $36.28 | N/A |
| Revenue Next Year | $20.85 | $1,127.34 |
| P/E Ratio | $425.29 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $35.58 | $6.97 |
| 52 Week High | $112.54 | $27.65 |
| Indicator | LIF | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 42.82 | 60.73 |
| Support Level | $37.61 | $19.23 |
| Resistance Level | $42.15 | $27.14 |
| Average True Range (ATR) | 2.28 | 1.16 |
| MACD | 0.38 | 0.28 |
| Stochastic Oscillator | 26.64 | 90.71 |
Life360 is the world's largest family focused social network, with nearly 100 million monthly active users. Security-conscious families use the Life360 app to track each other's whereabouts and to track the location of their pets and personal belongings. Life360 also offers a suite of additional security features, such as driver safety monitoring, roadside assistance, and emergency dispatching. In the US, the Life360 app regularly ranks in the top 10 most popular social-networking apps and in the top 25 across all apps in terms of daily active users.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.